{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:51Z","timestamp":1786119531220,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/mjt.0b013e3182053ee1","type":"journal-article","created":{"date-parts":[[2011,1,20]],"date-time":"2011-01-20T00:58:14Z","timestamp":1295485094000},"page":"569-571","source":"Crossref","is-referenced-by-count":8,"title":["Valproate-Induced Hyperammonemic Encephalopathy"],"prefix":"10.1097","volume":"20","author":[{"given":"K. Kiran","family":"Sunkavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad M.","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanth","family":"Koneru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210202","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"R2-20-20210202","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.","volume":"16","author":"Loscher","year":"2002","journal-title":"CNS Drugs"},{"key":"R3-20-20210202","first-page":"431","article-title":"Zahir S, et al..","volume":"9","author":"Lheureux","year":"2005","journal-title":"Science review: carnitine in the treatment of valproic acid-induced toxicity-what is the evidence Crit Care"},{"key":"R4-20-20210202","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-0082(98)00075-6","article-title":"Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action.","volume":"58","author":"Loscher","year":"1999","journal-title":"Prog Neurobiol"},{"key":"R5-20-20210202","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1248\/bpb.20.91","article-title":"Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs.","volume":"20","author":"Hiraoka","year":"1997","journal-title":"Biol Pharm Bull"},{"key":"R6-20-20210202","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2165\/00003495-199447020-00008","article-title":"Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy.","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"R7-20-20210202","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2125.1978.tb01713.x","article-title":". Pharmacokinetics of valproic acid after oral and intravenous administration.","volume":"5","author":"Perucca","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"R8-20-20210202","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.1978.tb01663.x","article-title":". Disposition of sodium valproate in epileptic patients.","volume":"5","author":"Perucca","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20-20210202","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00003088-198005010-00002","article-title":"Clinical pharmacokinetics of valproic acid.","volume":"5","author":"Gugler","year":"1980","journal-title":"Clin Pharmacokinet"},{"key":"R10-20-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-198510020-00003","article-title":"Concentration-effect relationships of valproic acid.","volume":"10","author":"Chadwick","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"R11-20-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2710.1993.tb00612.x","article-title":". Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications.","volume":"18","author":"Gomez Bellver","year":"1993","journal-title":"J Clin Pharm Ther"},{"key":"R12-20-20210202","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1081\/CLT-100102388","article-title":". Multicenter case series of valproic acid ingestion: serum concentrations and toxicity.","volume":"38","author":"Spiller","year":"2000","journal-title":"J Toxicol Clin Toxicol"},{"key":"R13-20-20210202","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0887-8994(97)00026-X","article-title":". Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.","volume":"16","author":"Gidal","year":"1997","journal-title":"Pediatr Neurol"},{"key":"R14-20-20210202","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S0140-6736(80)91773-0","article-title":"Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy.","volume":"1","author":"Coulter","year":"1980","journal-title":"Lancet"},{"key":"R15-20-20210202","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.54.1.230","article-title":". Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.","volume":"54","author":"Hamer","year":"2000","journal-title":"Neurology"},{"key":"R16-20-20210202","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/A:1021918104127","article-title":". Valproate-induced hyperammonemic encephalopathy.","volume":"17","author":"Verrotti","year":"2002","journal-title":"Metab Brain Dis"},{"key":"R17-20-20210202","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1528-1157.2002.42201.x","article-title":". Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy.","volume":"43","author":"Ziyeh","year":"2002","journal-title":"Epilepsia"},{"key":"R18-20-20210202","first-page":"1779","article-title":"Valproic acid-induced hyperammonemic encephalopathy: MR appearance.","volume":"15","author":"Baganz","year":"1994","journal-title":"AJNR Am J Neuroradiol"},{"key":"R19-20-20210202","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000081861","article-title":". Valproate-induced hyperammonemic encephalopathy: imaging findings on diffusion-weighted MRI.","volume":"52","author":"Grubben","year":"2004","journal-title":"Eur Neurol"},{"key":"R20-20-20210202","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(00)03600-X","article-title":"Neuropsychological effects of epilepsy and antiepileptic drugs.","volume":"357","author":"Kwan","year":"2001","journal-title":"Lancet"},{"key":"R21-20-20210202","first-page":"193","article-title":"Polard E, et al..","volume":"19","author":"Latour","year":"2004","journal-title":"Drug induced encephalopathy in six epileptic patients: topiramate valproate or both Hum Psychopharmacol"},{"key":"R22-20-20210202","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/106002809302700510","article-title":". Valproate-induced coma: case report and literature review.","volume":"27","author":"Duarte","year":"1993","journal-title":"Ann Pharmacother"},{"key":"R23-20-20210202","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/WNL.42.3.666","article-title":". Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy.","volume":"42","author":"Honeycutt","year":"1992","journal-title":"Neurology"},{"key":"R24-20-20210202","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(86)92714-5","article-title":"Valproate toxicity and ornithine carbamoyltransferase deficiency.","volume":"2","author":"Kay","year":"1986","journal-title":"Lancet"},{"key":"R25-20-20210202","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1212\/WNL.38.3.365","article-title":"Hepatic and renal contributions to valproic acid-induced hyperammonemia.","volume":"38","author":"Marini","year":"1988","journal-title":"Neurology"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045391-201309000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:47Z","timestamp":1786041947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201309000-00020"}},"subtitle":["A Case Report and Brief Review of the Literature"],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3182053ee1","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}